Editorial Charter · Independent Educational Guide Methodology & Boundaries

About Melanotans: An independent pharmacology field report

Melanotans is an independent educational publication covering melanocortin receptor biology, prescription medicines afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree), and online products sold as Melanotan I and II.

What this site is — and what it is not

Melanotans is a reader's guide built for people who want to inspect peer-reviewed pharmacology and official regulatory records without wading through commercial hype. Every dispatch explains technical vocabulary in passing on first use—from G protein-coupled receptors and endogenous antagonists to biased signaling and tandem mass spectrometry—so a general reader can follow every step while a specialist sees exact numbers and study scopes.

Just as clearly, Melanotans is not a laboratory, manufacturer, chemical supplier, pharmacy, clinic, or telehealth service. This site sells nothing, publishes no prices, promo codes, or product reviews, and names no peptide vendors, compounding pharmacies, or telehealth companies. It employs no fictional doctors or invented author credentials, makes no claims of personal peptide use, and never provides dosing protocols, administration instructions, or medical advice.

Source mix and editorial standards

The bibliography on /references catalogs 54 directly opened documents spanning primary research papers, peer-reviewed reviews, clinical trial reports, analytical chemistry and microbiology studies, individual clinical case reports, U.S. FDA prescribing labels and approval records, European Medicines Agency European Public Assessment Reports (EPARs), Federal Register notices, and national agency advisories. No vendor blogs, forum anecdotes treated as medical evidence, or secondary content farms are cited as authorities. Melanotans applies five editorial standards across every page:

  • Direct verification from opened documents: Non-obvious claims link directly from the words of the sentence to the cited source listed on the Primary Source Ledger using its final public URL.
  • Scope and study design preserved: Percentages, EC50 potency values, sample sizes, dates, and laboratory measurements state the species, assay system, and study design—keeping animal bioassays, single case reports, and randomized human trials clearly distinguished.
  • Industry funding disclosed: Where pivotal trials or reviews received pharmaceutical funding or manufacturer-funded editorial support (such as Clinuvel Pharmaceuticals, Palatin Technologies, AMAG Pharmaceuticals, or Rhythm Pharmaceuticals), that sponsorship is noted alongside the findings.
  • Dated verbatim regulatory standard: Our editorial standard is to present statements about drug approvals, indications, enforcement, or compounding as dated, whole-sentence quotations from the regulator's own opened document, setting related federal texts side by side rather than selecting only cautionary or permissive excerpts.
  • No dosing or clinical advice: Published clinical trials are summarized for what they measured and who qualified—never as schedules, amounts, or instructions for individual use.

Why color is an editorial rule here

Throughout Melanotans, visual color carries consistent categorical meaning rather than decoration:

  • Dry-Sky Slate (#1D4B63) marks the three prescription melanocortin medicines covered in Part II: afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree).
  • Desert Ochre (#8A4E08) marks editorial links, primary actions, online products sold as Melanotan I and II, clinical case reports, and regulatory warning records.
  • Warm Sandstone (#E8DCC6) marks neutral historical background, receptor biology, and editorial reference pages.